Sung Soo Ahn1, Byung-Woo Yoo1, Jason Jungsik Song1, Yong-Beom Park1, Soo-Kon Lee1, Sang-Won Lee2. 1. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 2. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. sangwonlee@yuhs.ac.
Abstract
AIM: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. METHODS: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. RESULTS: The median age was 32.0 years old, and 77 patients (85.5%) were women. Anti-Sm was found in 44 of 90 patients (48.8%). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0% of patients having anti-Sm vs. 56.5% of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95% confidence interval, 1.033, 7.976, P = 0.043). CONCLUSION: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.
AIM: We investigated whether anti-Smith (Sm) is associated with the outcome of kidney biopsy-proven lupus nephritis. METHODS: We retrospectively analyzed clinical, laboratory and histological results in 90 patients with kidney biopsy-proven lupus nephritis. We defined persistent administration of immunosuppressants for more than 3 months after the kidney biopsy as early poor outcome of lupus nephritis. We compared baseline variables and delta values of lupus nephritis-related variables between patients with and without anti-Sm. The independent predictive values for early poor outcome were analyzed using logistic regression analysis. RESULTS: The median age was 32.0 years old, and 77 patients (85.5%) were women. Anti-Sm was found in 44 of 90 patients (48.8%). When we analyzed the differences in delta values of variables reflecting the kidney function or the early poor outcome between patients with and without anti-Sm, we found significant difference in the early poor outcome between the two groups (80.0% of patients having anti-Sm vs. 56.5% of those not having anti-Sm, P = 0.022). In multivariate logistic regression analysis, along with age and Systemic Lupus Erythematosus Disease Activity Index, the presence of anti-Sm increased the potential of the early poor outcome of lupus nephritis (odds ratio 2.870, 95% confidence interval, 1.033, 7.976, P = 0.043). CONCLUSION: Our data suggest that anti-Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy-proven lupus nephritis during the follow-up period.
Authors: Liliana Michelle Gomez Mendez; Matthew D Cascino; Jay Garg; Tamiko R Katsumoto; Paul Brakeman; Maria Dall'Era; Richard John Looney; Brad Rovin; Leonard Dragone; Paul Brunetta Journal: Clin J Am Soc Nephrol Date: 2018-08-08 Impact factor: 8.237
Authors: Juliana de Andrade Rebouças Guimarães; Silvania da Conceição Furtado; Ana Cyra Dos Santos Lucas; Bruno Mori; José Fernando Marques Barcellos Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752
Authors: Mohammed Abd El Monem Teama; Marwa Adham El-Mohamdy; Fatma Abdellah Abdullah Mahmoud; Fatma Mohammed Badr Journal: Open Access Rheumatol Date: 2021-07-16
Authors: Prithvi Raj; Ran Song; Honglin Zhu; Linley Riediger; Dong-Jae Jun; Chaoying Liang; Carlos Arana; Bo Zhang; Yajing Gao; Benjamin E Wakeland; Igor Dozmorov; Jinchun Zhou; Jennifer A Kelly; Bernard R Lauwerys; Joel M Guthridge; Nancy J Olsen; Swapan K Nath; Chandrashekhar Pasare; Nicolai van Oers; Gary Gilkeson; Betty P Tsao; Patrick M Gaffney; Peter K Gregersen; Judith A James; Xiaoxia Zuo; David R Karp; Quan-Zhen Li; Edward K Wakeland Journal: Genome Biol Date: 2020-11-19 Impact factor: 17.906